To functionally characterize the importance of EGFR in mediating the cancer stemness properties directed by SPINK1, we treated HCC cells with recombinant SPINK1, in the absence or presence of EGFR knockdown (Supplementary Fig. S4a) or FDA-approved EGFR inhibitor, Erlotinib. Here, EGFR is linked to cancer.